Ocean Biomedical co-founder Jonathan Kurtis presents detailed data on malaria vaccine at conference
usx:ocea Blog PostOcean Biomedical (OCEA) announces patent award for novel cancer immunotherapy treatment
usx:ocea Blog PostOcean Biomedical announces loan commitment of up to $10 million from largest stockholder
usx:ocea Blog PostOcean Biomedical co-founder Jake Kurtis gets new patent for novel malaria vaccine target
usx:ocea Blog PostTaglich Brothers initiates coverage of Ocean Biomedical, with price target of $20
usx:ocea Blog PostOcean Biomedical’s JV partner Virion presents positive oncology data at SITC 2023
usx:ocea Blog PostAIRO Group Holdings all set to go public through SPAC merger
usx:avav usx:joby usx:evex usx:ocea usx:krnlu Blog PostOcean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
usx:ocea Blog PostOcean Biomedical provides positive research data on anti-tumor pathway; stock climbs
usx:ocea Blog PostFundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
usx:ocea Blog PostOcean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
usx:ocea Blog PostFundamental Research Corp. initiates coverage of Ocean Biomedical (OCEA) with “Buy” recommendation
usx:pfe usx:ocea Blog Post